Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Pelacarsen (Primary)
- Indications Hyperlipoproteinaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Akcea Therapeutics; Ionis Pharmaceuticals
- 22 Mar 2022 Results published in the Journal of the American College of Cardiology
- 08 Apr 2020 Results (n=32) assessing gene expression profile of circulating monocytes of healthy individuals and CVD patients, both with elevated Lp(a) in two studies (AKCEA-APO(a)-LRx study (NCT03070782) and the ANITSCHKOW study (NCT02729025)), published in the European Heart Journal.
- 02 Jan 2020 Results published in Akcea Therapeutics media release